HEADER APOPTOSIS 21-JAN-21 7LH7 TITLE CRYSTAL STRUCTURE OF BCL-XL IN COMPLEX WITH A BENZOTHIAZOLE-BASED TITLE 2 INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: BCL-2-LIKE PROTEIN 1; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: BCL2-L-1,APOPTOSIS REGULATOR BCL-X; COMPND 5 ENGINEERED: YES; COMPND 6 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: BCL2L1, BCL2L, BCLX; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS BCL-XL, APOPTOSIS, STRUCTURE-BASED DRUG DESIGN EXPDTA X-RAY DIFFRACTION AUTHOR R.A.JUDGE,Z.TAO REVDAT 2 18-OCT-23 7LH7 1 REMARK REVDAT 1 23-JUN-21 7LH7 0 JRNL AUTH Z.F.TAO,X.WANG,J.CHEN,J.P.INGRAM,S.JIN,R.A.JUDGE,P.J.KOVAR, JRNL AUTH 2 C.PARK,C.SUN,B.D.WAKEFIELD,L.ZHOU,H.ZHANG,S.W.ELMORE, JRNL AUTH 3 D.C.PHILLIPS,A.S.JUDD,J.D.LEVERSON,A.J.SOUERS JRNL TITL STRUCTURE-BASED DESIGN OF A-1293102, A POTENT AND SELECTIVE JRNL TITL 2 BCL-XL INHIBITOR JRNL REF ACS MEDICINAL CHEMISTRY V. 12 1011 2021 JRNL REF 2 LETTERS JRNL DOI 10.1021/ACSMEDCHEMLETT.1C00162 REMARK 2 REMARK 2 RESOLUTION. 1.41 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.7 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.41 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 46.69 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 99.1 REMARK 3 NUMBER OF REFLECTIONS : 76281 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.186 REMARK 3 R VALUE (WORKING SET) : 0.185 REMARK 3 FREE R VALUE : 0.199 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 3873 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 1.41 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 1.42 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.79 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : NULL REMARK 3 BIN R VALUE (WORKING + TEST SET) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2073 REMARK 3 BIN FREE R VALUE : 0.2043 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : 66 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2293 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 128 REMARK 3 SOLVENT ATOMS : 355 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 23.69 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -1.73040 REMARK 3 B22 (A**2) : 3.54230 REMARK 3 B33 (A**2) : -1.81190 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.180 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.057 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.056 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.054 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.053 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.954 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.939 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 2485 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 3370 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 862 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : NULL ; NULL ; NULL REMARK 3 GENERAL PLANES : 511 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 2485 ; 10.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 282 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 2694 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 0.86 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.59 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 13.69 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 7LH7 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 22-JAN-21. REMARK 100 THE DEPOSITION ID IS D_1000254245. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-JAN-11 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 4.2 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ALS REMARK 200 BEAMLINE : 5.0.3 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9765 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 315 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XDS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 76281 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.409 REMARK 200 RESOLUTION RANGE LOW (A) : 46.690 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.1 REMARK 200 DATA REDUNDANCY : 7.100 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 17.8000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.41 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.43 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: 6VWC REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 53.60 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.65 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20% (W/V) PEG 8000, 0.1 M PHOSPHATE REMARK 280 -CITRATE PH 4.2, 0.2 M SODIUM CHLORIDE. THE METHOD WAS LIQUID- REMARK 280 LIQUID COUNTER DIFFUSION, COUNTER-DIFFUSION, TEMPERATURE 290K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 2 2 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z+1/2 REMARK 290 3555 -X,Y,-Z+1/2 REMARK 290 4555 X,-Y,-Z REMARK 290 5555 X+1/2,Y+1/2,Z REMARK 290 6555 -X+1/2,-Y+1/2,Z+1/2 REMARK 290 7555 -X+1/2,Y+1/2,-Z+1/2 REMARK 290 8555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 75.73000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 75.73000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 29.43000 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 44.45500 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 6 -1.000000 0.000000 0.000000 29.43000 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 44.45500 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 75.73000 REMARK 290 SMTRY1 7 -1.000000 0.000000 0.000000 29.43000 REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 44.45500 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 75.73000 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 29.43000 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 44.45500 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1 REMARK 465 SER A 2 REMARK 465 GLY A 79 REMARK 465 GLU A 208 REMARK 465 ARG A 209 REMARK 465 LEU A 210 REMARK 465 GLU A 211 REMARK 465 HIS A 212 REMARK 465 HIS A 213 REMARK 465 HIS A 214 REMARK 465 HIS A 215 REMARK 465 HIS A 216 REMARK 465 HIS A 217 REMARK 465 MET B 1 REMARK 465 SER B 2 REMARK 465 GLN B 3 REMARK 465 SER B 23 REMARK 465 ALA B 24 REMARK 465 SER B 25 REMARK 465 GLY B 26 REMARK 465 GLY B 27 REMARK 465 GLY B 28 REMARK 465 GLY B 79 REMARK 465 GLY B 80 REMARK 465 GLY B 81 REMARK 465 GLY B 82 REMARK 465 ALA B 199 REMARK 465 ALA B 200 REMARK 465 ALA B 201 REMARK 465 GLU B 202 REMARK 465 SER B 203 REMARK 465 ARG B 204 REMARK 465 LYS B 205 REMARK 465 GLY B 206 REMARK 465 GLN B 207 REMARK 465 GLU B 208 REMARK 465 ARG B 209 REMARK 465 LEU B 210 REMARK 465 GLU B 211 REMARK 465 HIS B 212 REMARK 465 HIS B 213 REMARK 465 HIS B 214 REMARK 465 HIS B 215 REMARK 465 HIS B 216 REMARK 465 HIS B 217 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue XZM A 4000 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue XZM B 4000 DBREF 7LH7 A 1 25 UNP Q07817 B2CL1_HUMAN 1 25 DBREF 7LH7 A 83 209 UNP Q07817 B2CL1_HUMAN 83 209 DBREF 7LH7 B 1 25 UNP Q07817 B2CL1_HUMAN 1 25 DBREF 7LH7 B 83 209 UNP Q07817 B2CL1_HUMAN 83 209 SEQADV 7LH7 ALA A 24 UNP Q07817 TRP 24 ENGINEERED MUTATION SEQADV 7LH7 GLY A 26 UNP Q07817 LINKER SEQADV 7LH7 GLY A 27 UNP Q07817 LINKER SEQADV 7LH7 GLY A 28 UNP Q07817 LINKER SEQADV 7LH7 GLY A 79 UNP Q07817 LINKER SEQADV 7LH7 GLY A 80 UNP Q07817 LINKER SEQADV 7LH7 GLY A 81 UNP Q07817 LINKER SEQADV 7LH7 GLY A 82 UNP Q07817 LINKER SEQADV 7LH7 LYS A 158 UNP Q07817 GLU 158 ENGINEERED MUTATION SEQADV 7LH7 ALA A 189 UNP Q07817 ASP 189 ENGINEERED MUTATION SEQADV 7LH7 LEU A 210 UNP Q07817 EXPRESSION TAG SEQADV 7LH7 GLU A 211 UNP Q07817 EXPRESSION TAG SEQADV 7LH7 HIS A 212 UNP Q07817 EXPRESSION TAG SEQADV 7LH7 HIS A 213 UNP Q07817 EXPRESSION TAG SEQADV 7LH7 HIS A 214 UNP Q07817 EXPRESSION TAG SEQADV 7LH7 HIS A 215 UNP Q07817 EXPRESSION TAG SEQADV 7LH7 HIS A 216 UNP Q07817 EXPRESSION TAG SEQADV 7LH7 HIS A 217 UNP Q07817 EXPRESSION TAG SEQADV 7LH7 ALA B 24 UNP Q07817 TRP 24 ENGINEERED MUTATION SEQADV 7LH7 GLY B 26 UNP Q07817 LINKER SEQADV 7LH7 GLY B 27 UNP Q07817 LINKER SEQADV 7LH7 GLY B 28 UNP Q07817 LINKER SEQADV 7LH7 GLY B 79 UNP Q07817 LINKER SEQADV 7LH7 GLY B 80 UNP Q07817 LINKER SEQADV 7LH7 GLY B 81 UNP Q07817 LINKER SEQADV 7LH7 GLY B 82 UNP Q07817 LINKER SEQADV 7LH7 LYS B 158 UNP Q07817 GLU 158 ENGINEERED MUTATION SEQADV 7LH7 ALA B 189 UNP Q07817 ASP 189 ENGINEERED MUTATION SEQADV 7LH7 LEU B 210 UNP Q07817 EXPRESSION TAG SEQADV 7LH7 GLU B 211 UNP Q07817 EXPRESSION TAG SEQADV 7LH7 HIS B 212 UNP Q07817 EXPRESSION TAG SEQADV 7LH7 HIS B 213 UNP Q07817 EXPRESSION TAG SEQADV 7LH7 HIS B 214 UNP Q07817 EXPRESSION TAG SEQADV 7LH7 HIS B 215 UNP Q07817 EXPRESSION TAG SEQADV 7LH7 HIS B 216 UNP Q07817 EXPRESSION TAG SEQADV 7LH7 HIS B 217 UNP Q07817 EXPRESSION TAG SEQRES 1 A 167 MET SER GLN SER ASN ARG GLU LEU VAL VAL ASP PHE LEU SEQRES 2 A 167 SER TYR LYS LEU SER GLN LYS GLY TYR SER ALA SER GLY SEQRES 3 A 167 GLY GLY GLY GLY GLY GLY MET ALA ALA VAL LYS GLN ALA SEQRES 4 A 167 LEU ARG GLU ALA GLY ASP GLU PHE GLU LEU ARG TYR ARG SEQRES 5 A 167 ARG ALA PHE SER ASP LEU THR SER GLN LEU HIS ILE THR SEQRES 6 A 167 PRO GLY THR ALA TYR GLN SER PHE GLU GLN VAL VAL ASN SEQRES 7 A 167 GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY ARG ILE VAL SEQRES 8 A 167 ALA PHE PHE SER PHE GLY GLY ALA LEU CYS VAL GLU SER SEQRES 9 A 167 VAL ASP LYS LYS MET GLN VAL LEU VAL SER ARG ILE ALA SEQRES 10 A 167 ALA TRP MET ALA THR TYR LEU ASN ASP HIS LEU GLU PRO SEQRES 11 A 167 TRP ILE GLN GLU ASN GLY GLY TRP ALA THR PHE VAL GLU SEQRES 12 A 167 LEU TYR GLY ASN ASN ALA ALA ALA GLU SER ARG LYS GLY SEQRES 13 A 167 GLN GLU ARG LEU GLU HIS HIS HIS HIS HIS HIS SEQRES 1 B 167 MET SER GLN SER ASN ARG GLU LEU VAL VAL ASP PHE LEU SEQRES 2 B 167 SER TYR LYS LEU SER GLN LYS GLY TYR SER ALA SER GLY SEQRES 3 B 167 GLY GLY GLY GLY GLY GLY MET ALA ALA VAL LYS GLN ALA SEQRES 4 B 167 LEU ARG GLU ALA GLY ASP GLU PHE GLU LEU ARG TYR ARG SEQRES 5 B 167 ARG ALA PHE SER ASP LEU THR SER GLN LEU HIS ILE THR SEQRES 6 B 167 PRO GLY THR ALA TYR GLN SER PHE GLU GLN VAL VAL ASN SEQRES 7 B 167 GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY ARG ILE VAL SEQRES 8 B 167 ALA PHE PHE SER PHE GLY GLY ALA LEU CYS VAL GLU SER SEQRES 9 B 167 VAL ASP LYS LYS MET GLN VAL LEU VAL SER ARG ILE ALA SEQRES 10 B 167 ALA TRP MET ALA THR TYR LEU ASN ASP HIS LEU GLU PRO SEQRES 11 B 167 TRP ILE GLN GLU ASN GLY GLY TRP ALA THR PHE VAL GLU SEQRES 12 B 167 LEU TYR GLY ASN ASN ALA ALA ALA GLU SER ARG LYS GLY SEQRES 13 B 167 GLN GLU ARG LEU GLU HIS HIS HIS HIS HIS HIS HET XZM A4000 64 HET XZM B4000 64 HETNAM XZM N-(1,3-BENZOTHIAZOL-2-YL)-2-(4-{[(4-{[(2R)-4- HETNAM 2 XZM (MORPHOLIN-4-YL)-1-(PHENYLSULFANYL)BUTAN-2-YL]AMINO}- HETNAM 3 XZM 3-[(TRIFLUOROMETHYL)SULFONYL]PHENYL) HETNAM 4 XZM SULFONYL]CARBAMOYL}-1,3-THIAZOL-2-YL)-1,2,3,4- HETNAM 5 XZM TETRAHYDROISOQUINOLINE-8-CARBOXAMIDE FORMUL 3 XZM 2(C42 H40 F3 N7 O7 S5) FORMUL 5 HOH *355(H2 O) HELIX 1 AA1 GLN A 3 GLN A 19 1 17 HELIX 2 AA2 MET A 83 TYR A 101 1 19 HELIX 3 AA3 ARG A 102 PHE A 105 5 4 HELIX 4 AA4 ASP A 107 GLN A 111 5 5 HELIX 5 AA5 ALA A 119 ARG A 132 1 14 HELIX 6 AA6 ASN A 136 LYS A 157 1 22 HELIX 7 AA7 VAL A 161 LEU A 178 1 18 HELIX 8 AA8 LEU A 178 ASN A 185 1 8 HELIX 9 AA9 GLY A 186 GLY A 196 1 11 HELIX 10 AB1 ASN A 198 LYS A 205 1 8 HELIX 11 AB2 ASN B 5 LYS B 20 1 16 HELIX 12 AB3 ALA B 84 TYR B 101 1 18 HELIX 13 AB4 ARG B 102 PHE B 105 5 4 HELIX 14 AB5 ASP B 107 LEU B 112 5 6 HELIX 15 AB6 ALA B 119 GLU B 129 1 11 HELIX 16 AB7 LEU B 130 ARG B 132 5 3 HELIX 17 AB8 ASN B 136 LYS B 157 1 22 HELIX 18 AB9 VAL B 161 LEU B 178 1 18 HELIX 19 AC1 LEU B 178 ASN B 185 1 8 HELIX 20 AC2 GLY B 186 GLY B 196 1 11 SITE 1 AC1 29 GLU A 96 PHE A 97 TYR A 101 ARG A 102 SITE 2 AC1 29 PHE A 105 SER A 106 ASP A 107 LEU A 108 SITE 3 AC1 29 THR A 109 GLU A 129 LEU A 130 ASN A 136 SITE 4 AC1 29 TRP A 137 GLY A 138 ARG A 139 ALA A 142 SITE 5 AC1 29 SER A 145 PHE A 146 PHE A 191 GLU A 193 SITE 6 AC1 29 LEU A 194 TYR A 195 ASN A 197 ASN A 198 SITE 7 AC1 29 HOH A4128 HOH A4206 HOH A4230 HOH A4234 SITE 8 AC1 29 ALA B 104 SITE 1 AC2 28 ALA A 104 GLN A 183 GLU A 184 GLY A 186 SITE 2 AC2 28 ALA B 93 GLU B 96 PHE B 97 TYR B 101 SITE 3 AC2 28 PHE B 105 SER B 106 ASP B 107 LEU B 108 SITE 4 AC2 28 GLU B 129 LEU B 130 ASN B 136 TRP B 137 SITE 5 AC2 28 GLY B 138 ARG B 139 VAL B 141 ALA B 142 SITE 6 AC2 28 SER B 145 PHE B 146 PHE B 191 TYR B 195 SITE 7 AC2 28 ASN B 197 ASN B 198 HOH B4144 HOH B4201 CRYST1 58.860 88.910 151.460 90.00 90.00 90.00 C 2 2 21 16 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.016989 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011247 0.000000 0.00000 SCALE3 0.000000 0.000000 0.006602 0.00000